The content on this site is intended for healthcare professionals only
Dr Sylvie Bonvalot talks with ecancer at the 2012 ESMO meeting in Vienna about the strategy of treatment for desmoid tumours.
Desmoid tumours, a rare type of aggressive tumour, can present in almost any part of the body.
The most important part of diagnosis for this tumour type is testing for a beta kinase mutation that 95% of patients have.
The main advances come specifically in altering strategy on approaching treatment as half of patients receiving treatment cannot continue after the first course because of adverse side effects.
Filming supported by Amgen
SIOG 2024: Updates in medical oncology
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Multiple Myeloma: evolving paradigm - Panel Discussion
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Choosing the right patients for transplant
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
